CoChat

Long-Term Safety of OROS Methylphenidate in Adults With Attention-Deficit/Hyperactivity Disorder: An Open-Label, Dose-Titration, 1-Year Study

Adler, Lenard A., Orman, Camille, Starr, H. Lynn, Silber, Steve, Palumbo, Joseph, Cooper, Kimberly, Berwaerts, Joris, Harrison, Diane D. · 2011 · Journal of Clinical Psychopharmacology
Cited by 47

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To evaluate the long-term safety of OROS methylphenidate in the management of attention-deficit/hyperactivity disorder (ADHD) in adults. METHODS: This multicenter, open-label, dose-titration, flexible dose study enrolled adults with ADHD for 6 or 12 months of treatment with OROS methylphenidate. Dosing began at 36 mg/d, with titration in 18-mg increments every 7 days until a predefined outcome (efficacy threshold, maximum dosage of 108 mg/d, or limiting adverse event). Dose reduction occurred for prespecified reasons, and the subjects discontinued if unable to tolerate 36 mg/d. Assessments included ADHD symptoms, adverse events, vital signs, and laboratory results. RESULTS: A total of 550 subjects received treatment (52% were men; mean age, 39 years; range, 18-65 years), and 57% (146/258) and 44% (129/292) completed their 6 or 12 months of treatment with mean durations of 128 and 213 days, respectively. The final prescribed dosages were 36 mg/d (22.4%), 54 mg/d (25.1%), 72 mg/d (22.0%), 90 mg/d (17.1%), and 108 mg/d (13.5%). Modest increases from baseline to final visit were observed in mean systolic (2.6 mm Hg) and diastolic (1.9 mm Hg) blood pressure and pulse (4.1 beats per minute). The mean weight decreased by 2.3 kg. No clinically meaningful changes in laboratory values or electrocardiogram parameters were observed other than increased heart rate. Most common adverse events included decreased appetite (26.7%), headache (24.0%), and insomnia (20.7%). No serious adverse event was considered related to study medication. Several measures of efficacy indicated improvement during the study. CONCLUSIONS: OROS methylphenidate, in the flexible dosage range from 36 to 108 mg/d, was well tolerated for up to 1 year in adults with ADHD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jcp.0b013e318203ea0a

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 47

Metadata

Authors
Adler, L. A., Orman, C., Starr, H. L., Silber, S., Palumbo, J., Cooper, K., Berwaerts, J., & Harrison, D. D.
Venue
Journal of Clinical Psychopharmacology
Published
2011-02
Volume
31
Issue
1
Pages
108-114
ISSN
0271-0749 (ISSN-L)
OpenAlex
W2016546088
Cited by
47
References
12
FWCI
1.79
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-Term Safety of OROS Methylphenidate in Adults With Attention-Deficit/Hyperactivity Disorder: An Open-Label, Dose-Titration, 1-Year Study. https://app.cochat.ai/papers/10.1097/jcp.0b013e318203ea0a
The paper
Adler, L. A., Orman, C., Starr, H. L., Silber, S., Palumbo, J., Cooper, K., Berwaerts, J., & Harrison, D. D. (2011). Long-Term Safety of OROS Methylphenidate in Adults With Attention-Deficit/Hyperactivity Disorder: An Open-Label, Dose-Titration, 1-Year Study. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e318203ea0a

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.